Lifecare AS (DE:LFC0) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Lifecare ASA, a medical sensor company, has completed drafting a protocol for a pivotal human clinical study targeting regulatory approval for its innovative Continuous Glucose Monitor, Sencell. The submission of the study protocol is scheduled for the end of 2024, with plans to engage a Contract Research Organization and finalize study site selections, including a site in Mainz, Germany. CEO Joacim Holter expresses confidence in meeting the end-of-year targets and proceeding with the CE study for clinical use.
For further insights into DE:LFC0 stock, check out TipRanks’ Stock Analysis page.
